1. Home
  2. Analysis
  3. Fluorouracil
  4. Nodular-regenerative-hyperplasia

Fluorouracil and Nodular regenerative hyperplasia - a phase IV clinical study of FDA data

Summary:

Nodular regenerative hyperplasia is reported as a side effect among people who take Fluorouracil (fluorouracil), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Oxaliplatin, and have Colon cancer.

The phase IV clinical study analyzes which people have Nodular regenerative hyperplasia when taking Fluorouracil. It is created by eHealthMe based on reports of 96,940 people who have side effects when taking Fluorouracil from the FDA, and is updated regularly.

What is Fluorouracil?

Fluorouracil has active ingredients of fluorouracil. It is often used in colon cancer metastatic. eHealthMe is studying from 97,087 Fluorouracil users. Check the latest studies of Fluorouracil.

What is Nodular regenerative hyperplasia?

Nodular regenerative hyperplasia (regeneration of a skin condition characterized by crops of small, tender, erythematous nodules on the legs) is found to be associated with 43 drugs and 144 conditions by eHealthMe. Check the latest studies of Nodular regenerative hyperplasia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

96,940 people reported to have side effects when taking Fluorouracil.
Among them, 77 people (0.08%) have Nodular regenerative hyperplasia.

Could Fluorouracil cause Nodular regenerative hyperplasia?

Among these 77 people:

How long have people been on Fluorouracil when they have Nodular regenerative hyperplasia? *

  • < 1 month: 38.46 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 38.46 %
  • 1 - 2 years: 7.69 %
  • 2 - 5 years: 15.38 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Nodular regenerative hyperplasia when taking Fluorouracil? *

  • female: 45.1 %
  • male: 54.9 %

What is the age of people who have Nodular regenerative hyperplasia when taking Fluorouracil? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 3.51 %
  • 40-49: 31.58 %
  • 50-59: 24.56 %
  • 60+: 40.35 %

What are other drugs people take besides Fluorouracil? *

  1. Oxaliplatin: 28 people, 36.36%
  2. Avastin: 11 people, 14.29%
  3. Eloxatin: 6 people, 7.79%
  4. Leucovorin Calcium: 5 people, 6.49%
  5. Neupogen: 3 people, 3.90%
  6. Eprex: 3 people, 3.90%
  7. Dexamethasone: 3 people, 3.90%
  8. Erbitux: 2 people, 2.60%
  9. Cisplatin: 2 people, 2.60%
  10. Avandamet: 2 people, 2.60%

What are other side effects people have besides Nodular regenerative hyperplasia? *

  1. Venoocclusive Liver Disease (small veins in the liver are obstructed): 31 people, 40.26%
  2. Portal Hypertension (increase in the blood pressure within a system of veins called the portal venous system): 15 people, 19.48%
  3. Varices Oesophageal (enlarged and swollen veins at the bottom of the oesophagus, near the stomach): 13 people, 16.88%
  4. Splenomegaly (enlargement of spleen): 11 people, 14.29%
  5. Hepatic Failure (liver failure): 8 people, 10.39%
  6. Pvt: 8 people, 10.39%
  7. Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 7 people, 9.09%
  8. Ascites (accumulation of fluid in the abdominal cavity): 6 people, 7.79%
  9. Hepatocellular Carcinoma (liver cancer): 6 people, 7.79%
  10. Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 6 people, 7.79%

What are the existing conditions these people have? *

  1. Colon Cancer: 26 people, 33.77%
  2. Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 13 people, 16.88%
  3. Metastases To Liver (cancer spreads to liver): 9 people, 11.69%
  4. Rectosigmoid Cancer Metastatic (cancer that originates in the rectum and sigmoid colon and spreads to other part): 6 people, 7.79%
  5. Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 3 people, 3.90%
  6. Rectal Cancer Metastatic (cancer of rectum spreads to other): 2 people, 2.60%
  7. Venoocclusive Liver Disease (small veins in the liver are obstructed): 1 person, 1.30%
  8. Pain: 1 person, 1.30%
  9. Metastases To Lymph Nodes (cancer spreads to lymph node): 1 person, 1.30%
  10. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 1.30%

* Approximation only. Some reports may have incomplete information.

Do you take Fluorouracil and have Nodular regenerative hyperplasia?

- Check whether Nodular regenerative hyperplasia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fluorouracil:

Nodular regenerative hyperplasia treatments and more:

How severe was Nodular regenerative hyperplasia and when was it recovered:

Expand to all the drugs that have ingredients of fluorouracil:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fluorouracil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nodular regenerative hyperplasia:

Browse all the conditions that are associated with Nodular regenerative hyperplasia:

How the study uses the data?

The study uses data from the FDA. It is based on fluorouracil (the active ingredients of Fluorouracil) and Fluorouracil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.